Cleared Traditional

K123880 - QUANTA FLASH CENTROMERE

K123880 is an FDA 510(k) clearance for QUANTA FLASH CENTROMERE, manufactured by Inova Diagnostics, Inc.. The device is a Class 2 Immunology device with product code LJM cleared through the Traditional 510(k) pathway after a 417-day FDA review.

K123880 · Inova Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2014
Decision
417d
Days
Class 2
Risk

K123880 is an FDA 510(k) clearance for the QUANTA FLASH CENTROMERE. Classified as Antinuclear Antibody (enzyme-labeled), Antigen, Controls (product code LJM), Class II - Special Controls.

Submitted by Inova Diagnostics, Inc. (San Diego, US). The FDA issued a Cleared decision on February 7, 2014 after a review of 417 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Immunology submissions.

View all Inova Diagnostics, Inc. devices

FDA 510(k) Submission Details - K123880

510(k) Number K123880 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 17, 2012
Decision Date February 07, 2014
Days to Decision 417 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
312d slower than avg
Panel avg: 105d · This submission: 417d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LJM Device Classification - Class 2, Special Controls

Product Code LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls

All 70
Devices cleared under the same product code (LJM) and FDA review panel - the closest regulatory comparables to K123880.
EliA CENP Immunoassay, EliA U1RNP Immunoassay, EliA RNP70 Immunoassay
K182353 · Phadia AB · Nov 2018
ImmuLisa Enhanced Centromere Antibody ELISA
K151559 · Immco Diagnostics, Inc. · Mar 2016
VARELISA RECOMBI ANA SCREEN, MODEL 12 596
K083188 · Phadia US, Inc. · Mar 2009
IMMULISA ANTINUCLEAR ANTIBODY SCREEN ELISA
K041102 · Immco Diagnostics, Inc. · Oct 2004
EL-ANA PROFILES: ANTI-CHROMATIN
K040291 · Theratest Laboratories, Inc. · Mar 2004
THE THERATEST EL-ANA PROFILES: ANTI-CENTROMERE
K024031 · Theratest Laboratories, Inc. · Feb 2003